Risk Factors for Artificial Urinary Sphincter Explantation and Erosion in Male Nonneurological Patients.

Artificial urinary sphincter Radiotherapy Stress urinary incontinence

Journal

International neurourology journal
ISSN: 2093-4777
Titre abrégé: Int Neurourol J
Pays: Korea (South)
ID NLM: 101534513

Informations de publication

Date de publication:
Jun 2024
Historique:
received: 06 02 2024
accepted: 23 04 2024
medline: 3 7 2024
pubmed: 3 7 2024
entrez: 3 7 2024
Statut: ppublish

Résumé

This study was performed to assess the risk factors for artificial urinary sphincter (AUS) explantation in a large multicenter cohort. We retrospectively reviewed the medical records for all 1,233 implantations of the AMS-800 AUS device in male nonneurological patients from 2005 to 2020 across 13 French centers. Patients with neurological conditions were excluded from the study. To identify factors associated with explantation-free survival, survival analysis was performed. Explantation was defined as the complete removal of the device, whereas revision referred to the replacement of the device or its components. The study included 1,107 patients, of whom 281 underwent AUS explantation. The median survival without explantation was 83 months. The leading causes of explantation were infection and erosion. Univariate analysis revealed several significant risk factors for explantation: age above 75 years (34.6% in the explanted group vs. 25.8% in the nonexplanted group, P=0.007), history of radiotherapy (43.5% vs. 31.3%, P=0.001), and anticoagulant use (15% vs. 8.6%, P<0.001). In logistic regression analysis, the only significant risk factor was previous radiotherapy (odds ratio [OR], 2.05; P<0.05). Cox proportional hazards analysis revealed 2 factors associated with earlier explantation: transcorporal cuff implantation (hazard ratio [HR], 2.67; P=0.01) and the annual caseload of the center (HR, 1.08; P=0.02). When specifically examining explantation due to erosion, radiotherapy was the sole factor significantly associated with the risk of erosion (OR, 2.47; P<0.05) as well as earlier erosion (HR, 1.90; P=0.039). In this series, conducted in a real-world setting across multiple centers with different volumes and levels of expertise, the median survival without AUS explantation was 83 months. This study confirms that radiotherapy represents the primary independent risk factor for AUS erosion in male nonneurological patients.

Identifiants

pubmed: 38956774
pii: inj.2448086.043
doi: 10.5213/inj.2448086.043
doi:

Types de publication

Journal Article

Langues

eng

Pagination

147-155

Auteurs

Alice Pitout (A)

Nancy Regional University Hospital Center Department of Urology, Nancy, France.

Pierre Lecoanet (P)

Clinic Louis Pasteur Department of Urology, Essey-lès-Nancy, France.

Charles Mazeaud (C)

Nancy Regional University Hospital Center Department of Urology, Nancy, France.

Victor Gaillard (V)

University Hospital of Strasbourg, Strasbourg, France.

Baptiste Poussot (B)

University Hospital of Strasbourg, Strasbourg, France.

Thibault Tricard (T)

University Hospital of Strasbourg, Strasbourg, France.

Christian Saussine (C)

University Hospital of Strasbourg, Strasbourg, France.

Thibaut Brierre (T)

University Hospital of Toulouse, Toulouse, France.

Xavier Game (X)

University Hospital of Toulouse, Toulouse, France.

Florian Beraud (F)

University Hospital of Lille, Lille, France.

Xavier Biardeau (X)

University Hospital of Lille, Lille, France.

Franck Bruyere (F)

University Hospital of Tours, Tours, France.

Damien Robin (D)

University Hospital of Paris, Paris, France.

Mehdi El-Akri (M)

University Hospital of Rennes Department of Urology, Rennes, France.

Daniel Chevallier (D)

University Hospital of Nice Department of Urology, Nice, France.

Tiffany Cousin (T)

University Hospital of Bordeaux, Bordeaux, France.

Grégoire Capon (G)

University Hospital of Bordeaux, Bordeaux, France.

Jean-Nicolas Cornu (JN)

University Hospital of Rouen, Rouen, France.

Hugo Dupuis (H)

University Hospital of Rouen, Rouen, France.

Hervé Monsaint (H)

Centre Medipole, Vannes, France.

Nicolas Hermieu (N)

University Hospital of Paris, Paris, France.

Jean-François Hermieu (JF)

University Hospital of Paris, Paris, France.

Priscilla Léon (P)

Clinic Pasteur, Royan, France.

Benoit Peyronnet (B)

University Hospital of Rennes Department of Urology, Rennes, France.

Imad Bentellis (I)

University Hospital of Nice Department of Urology, Nice, France.

Classifications MeSH